Impact on the Physical Activity Level of Coronary Patients in Phase 3 of a Therapeutic Educational Consolidation Program Involving a "Patient Partner" Associated With a Healthcare Professional. A Randomized Controlled Trial.

简要总结

详细描述

Following myocardial infarction, cardiac rehabilitation has shown undeniable benefits on strong criteria such as cardiovascular mortality and coronary recurrence. Cardiac rehabilitation consists of 3 phases: 1. immediate post-acute, in a cardiology department, 2. active cardiac rehabilitation for several weeks under medical supervision as an inpatient or outpatient, 3. Resumption of active life by the patient: one of the major aims of secondary prevention is long-term adherence to physical activity. The importance of phase 2 of cardiac rehabilitation is particularly emphasized and is the subject of recommendations by learned societies. The aim is to re-train the patient under paramedical and medical supervision, and to induce behavioral changes through specific therapeutic education. Exercise re-training aims to increase the patient's cardiorespiratory functional capacity and their ability to do physical activity of moderate-to-sustained intensity. One of the most commonly used units to calculate the intensity of physical activity is the Metabolic Equivalent of Task (MET). The higher the intensity of the activity, the higher the number of METs. Physical activity of at least moderate intensity, as recommended in the long-term care of coronary patients corresponds to 3 METs. The therapeutic objective by international recommendations, and explained to patients during phase 2 CR, is to achieve 150 minutes a week of moderate-to-sustained physical activity (3 METs or more). However, only 20% to 40% of coronary patients remain physically active at 6 months or 1 year, which means that the effects of Phase 2 cardiac rehabilitation are not maintained. Managing to maintain at least a moderate level of physical activity after phase 2 of CR, is a major objective. Various interventions (booklets, applications, activity programs, motivational talks led by healthcare professionals have been tested and compared with the usual care in Phase 3 cardiac rehabilitation. An effect seems to exist on the level of physical activity reported, but with a significant evaluation bias. Objective, validated measures of physical activity such as accelerometry have not proved their long-term efficacy (6 months being the classically explored endpoint). An intervention establishing a patient-centered relationship and cognitive-behavioral elements would seem to be a perspective of choice to be explored, therapeutic education having been little explored in phase 3 of cardiac rehabilitation and in the long term. To address some of the barriers identified in qualitative studies, the joint participation of a "patient partner" would seem to of interest. The PP is a patient who has acquired knowledge of their disease over time, through experience and experience and therapeutic education. They encourage dialogue between care teams and patients, facilitating patients' self-expression, and contributes to a better understanding of the discourse. The hypothesis is that a therapeutic educational consolidation program, involving a "patient partner" associated with a health professional, will increase the level of physical activity of coronary patients in Phase 3 of cardiac rehabilitation. The main objective of this study is to use accelerometry to evaluate the 6-month efficacy of the therapeutic education program for consolidation in phase 3 of Cardiovascular Rehabilitation involving a patient partner and a caregiver on the level of moderate to sustained physical activity (\> 3 METs) in coronary patients on Phase 3 of cardiac rehabilitation compared with usual rehabilitation management.

主要结局

次要结局

• Triglycerides in the Experimental Group(Month 6)
• Number of steps taken per week in the Experimental Group(Month 6)
• Blood pressure in Controls(Month 6)
• Modified Borg score in Controls(Month 6)
• Abdominal circumference in Controls(Month 6)
• Aerobic capacity in the Experimental Group(Month 6)
• Moderate-to-sustained physical activity in the Experimental Group(Month 3)
• Moderate-to-sustained physical activity in Controls(Month 3)
• Number of steps taken per week in Controls(Month 6)
• Modified Borg score in the Experimental Group(Month 6)
• Time spent sitting/lying down per week in Controls(Month 6)
• International Physical Activity Questionnaire Score in the Experimental Group(Month 6)
• International Physical Activity Questionnaire Score in Controls(Month 6)
• Time spent sitting/lying down per week in the Experimental Group(Month 6)
• Blood pressure in the Experimental Group(Month 6)
• Aerobic capacity in Controls(Month 6)
• Cholesterol in the Experimental Group(Month 6)
• Cholesterol in Controls(Month 6)
• Low-density lipoprotein in Controls(Month 6)
• High-density lipoprotein in the Experimental Group(Month 6)
• Abdominal circumference in the Experimental Group(Month 6)
• Low-density lipoprotein in the Experimental Group(Month 6)
• High-density lipoprotein in Controls(Month 6)
• Compliance with medication in the Experimental Group(Month 6)
• Mediterranean diet adherence test in Controls(Month 6)
• Understanding barriers to motivation: Experimental group(Month 6)
• Understanding barriers to motivation in Controls(Month 6)
• Blood glucose levels in the Experimental Group(Month 6)
• Motivation for doing physical activity in Controls(Month 6)
• Triglycerides in Controls(Month 6)
• Compliance with medication in Controls(Month 6)
• Exercise Confidence Survey in the Experimental Group(Month 6)
• Exercise Confidence Survey in Controls(Month 6)
• Blood glucose levels in Controls(Month 6)
• Motivation for doing physical activity in the Experimental Group(Month 6)
• Mediterranean diet adherence test in the Experimental Group(Month 6)
• Number of steps taken per week in the Experimental Group(Month 0)
• Number of steps taken per week in the Experimental Group(Month 3)
• Number of steps taken per week in Controls(Month 0)
• Number of steps taken per week in Controls(Month 3)
• Time spent sitting/lying down per week in the Experimental Group(Month 0)
• Time spent sitting/lying down per week in the Experimental Group(Month 3)
• Time spent sitting/lying down per week in Controls(Month 0)
• Time spent sitting/lying down per week in Controls(Month 3)
• International Physical Activity Questionnaire Score in the Experimental Group(Month 0)
• International Physical Activity Questionnaire Score in the Experimental Group(Month 3)
• International Physical Activity Questionnaire Score in Controls(Month 0)
• International Physical Activity Questionnaire Score in Controls(Month 3)
• Blood pressure in the Experimental Group(Month 0)
• Blood pressure in the Experimental Group(Month 3)
• Blood pressure in Controls(Month 0)
• Blood pressure in Controls(Month 3)
• Modified Borg score in the Experimental Group(Month 0)
• Modified Borg score in the Experimental Group(Month 3)
• Modified Borg score in Controls(Month 0)
• Modified Borg score in Controls(Month 3)
• Abdominal circumference in the Experimental Group(Month 0)
• Abdominal circumference in the Experimental Group(Month 3)
• Abdominal circumference in Controls(Month 0)
• Abdominal circumference in Controls(Month 3)
• Aerobic capacity in the Experimental Group(Month 0)
• Aerobic capacity in the Experimental Group(Month 3)
• Aerobic capacity in Controls(Month 0)
• Aerobic capacity in Controls(Month 3)
• Cholesterol in the Experimental Group(Month 0)
• Cholesterol in the Experimental Group(Month 3)
• Cholesterol in Controls(Month 0)
• Cholesterol in Controls(Month 3)
• Low-density lipoprotein in the Experimental Group(Month 0)
• Low-density lipoprotein in the Experimental Group(Month 3)
• Low-density lipoprotein in Controls(Month 0)
• Low-density lipoprotein in Controls(Month 3)
• High-density lipoprotein in the Experimental Group(Month 0)
• High-density lipoprotein in the Experimental Group(Month 3)
• High-density lipoprotein in Controls(Month 0)
• High-density lipoprotein in Controls(Month 3)
• Triglycerides in the Experimental Group(Month 0)
• Triglycerides in the Experimental Group(Month 3)
• Triglycerides in Controls(Month 0)
• Triglycerides in Controls(Month 3)
• Blood glucose levels in the Experimental Group(Month 0)
• Blood glucose levels in the Experimental Group(Month 3)
• Blood glucose levels in Controls(Month 0)
• Blood glucose levels in Controls(Month 3)
• Compliance with medication in the Experimental Group(Month 0)
• Compliance with medication in the Experimental Group(Month 3)
• Compliance with medication in Controls(Month 0)
• Compliance with medication in Controls(Month 3)
• Motivation for doing physical activity in the Experimental Group(Month 0)
• Motivation for doing physical activity in the Experimental Group(Month 3)
• Motivation for doing physical activity in Controls(Month 0)
• Motivation for doing physical activity in Controls(Month 3)
• Exercise Confidence Survey in the Experimental Group(Month 0)
• Exercise Confidence Survey in the Experimental Group(Month 3)
• Exercise Confidence Survey in Controls(Month 0)
• Exercise Confidence Survey in Controls(Month 3)
• Mediterranean diet adherence test in the Experimental Group(Month 0)
• Mediterranean diet adherence test in the Experimental Group(Month 3)
• Mediterranean diet adherence test in Controls(Month 0)
• Mediterranean diet adherence test in Controls(Month 3)
• Understanding barriers to motivation: Experimental group(Month 0)
• Understanding barriers to motivation: Experimental group(Month 3)
• Understanding barriers to motivation in Controls(Month 0)
• Understanding barriers to motivation in Controls(Month 3)